8-K: Moleculin Biotech Faces Nasdaq Delisting Warning

Moleculin Biotech received a delisting warning from Nasdaq for failing to maintain a minimum bid price, despite a recent reverse stock split.

Summary

• Moleculin Biotech, Inc. received a notification from Nasdaq on September 15, 2026, indicating non-compliance with the minimum bid price requirement.
• The company's common stock closing bid price has been below $1.00 for 30 consecutive business days, from July 31, 2026, to September 11, 2026.
• Due to a prior 1-for-25 reverse stock split effected on December 1, 2025, the company is not eligible for the standard 180-day compliance period.
• Moleculin Biotech intends to request a hearing before the Nasdaq Hearings Panel to appeal the determination and seek continued listing.
• Trading of the company's common stock will continue on The Nasdaq Capital Market pending the Panel's decision.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the company's non-compliance with Nasdaq's minimum bid price requirement and ineligibility for a standard compliance period, indicating significant financial distress.

Positives

• The company intends to request a hearing before the Nasdaq Hearings Panel, providing an opportunity to appeal the delisting notice.
• The company's common stock will continue to trade on The Nasdaq Capital Market pending the outcome of the hearing process.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement for continued listing.
• The company's common stock has traded below $1.00 for 30 consecutive business days.
• The company is ineligible for the standard 180-day compliance period due to a recent reverse stock split.
• There is no assurance that the company's request for continued listing will be granted or that compliance will be regained.

Risks

• The Nasdaq Hearings Panel may deny the company's request for continued listing.
• Continued listing may be conditioned on requirements that the company cannot satisfy.
• The company may not be able to regain and maintain compliance with the Minimum Bid Price Requirement.
• The company may not be able to maintain compliance with all other applicable Nasdaq continued listing requirements.
• Potential for increased volatility and reduced investor confidence due to the delisting warning.

Future Outlook

The company intends to request a hearing before the Nasdaq Hearings Panel. There can be no assurance that the company's request for continued listing will be granted or that the company will be able to regain and maintain compliance with the Minimum Bid Price Requirement or all other applicable requirements for continued listing on The Nasdaq Capital Market.

Management Comments

• The Company intends to make a timely request for a hearing before the Nasdaq Hearings Panel, in accordance with the procedures set forth in the Nasdaq Listing Rule 5800 Series.
• A timely request for a hearing will stay any suspension or delisting action pending the Panels decision, and the Companys Common Stock will continue to trade on The Nasdaq Capital Market during the pendency of the hearing process.
• There can be no assurance that the Companys request for continued listing will be granted or that the Company will be able to regain and maintain compliance with the Minimum Bid Price Requirement or all other applicable requirements for continued listing on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that Nasdaq's minimum bid price requirement is a common hurdle for companies experiencing significant stock price declines. Failure to meet this can lead to delisting, impacting liquidity and investor perception. Companies often resort to reverse stock splits to artificially boost share price, but Nasdaq's rules can penalize those who do so without sustained improvement in underlying business performance.

Stakeholder Impact

• Shareholders: Potential for increased stock price volatility, reduced liquidity, and negative market sentiment, which could lead to a decrease in share value.
• Creditors: May view the company as higher risk, potentially impacting future borrowing capabilities or terms.
• Potential Investors: May be deterred from investing due to the delisting risk and perceived financial instability.

Next Steps

• Request a hearing before the Nasdaq Hearings Panel.
• Present the company's case for continued listing to the Panel.
• Attempt to regain and maintain compliance with Nasdaq's listing requirements.

Key Dates

Recommendation

The company's failure to meet Nasdaq's minimum bid price requirement, coupled with its ineligibility for a standard compliance period due to a prior reverse stock split, signals significant financial distress and a high risk of delisting. This situation is likely to negatively impact the stock price and investor confidence, making it a sell recommendation.

Keywords

Nasdaq delisting, minimum bid price, compliance, reverse stock split, hearings panel, continued listing, stock price